2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. Journal Of The National Comprehensive Cancer Network 2022, 20: 436-442. PMID: 35545171, DOI: 10.6004/jnccn.2022.0026.Peer-Reviewed Original ResearchConceptsChemotherapy-induced anemiaChemotherapy-induced thrombocytopeniaHematopoietic growth factorsFebrile neutropeniaNCCN guidelinesGrowth factorTreatment of FNNCCN Guidelines InsightsIndividual patient's conditionAdult patientsSupportive careNonmyeloid malignanciesClinical managementPatient's conditionPatientsCancer treatmentAppropriate useRecent updatesPreventionGuidelinesTreatmentManagement optionsNeutropeniaThrombocytopeniaSequelae
2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports In Oncology 2021, 14: 430-438. PMID: 33790764, PMCID: PMC7983595, DOI: 10.1159/000514345.Peer-Reviewed Original ResearchMetastatic extramammary Paget's diseaseExtramammary Paget's diseaseStandard therapyPaget's diseaseTreatment responsePrimary cutaneous extramammary Paget diseaseCutaneous extramammary Paget's diseaseHigh PD-L1 expressionHigh tumor mutation burdenCycles of ipilimumabDurable partial responseImmune checkpoint inhibitionImmune checkpoint inhibitorsPD-L1 expressionCheckpoint inhibitor immunotherapyRare clinical entityTumor mutation burdenMetastatic tumor tissueCombination ipilimumabCheckpoint inhibitorsMetastatic diseaseCytotoxic chemotherapyPartial responseCheckpoint inhibitionClinical entity
2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. Journal Of The National Comprehensive Cancer Network 2020, 19: 1-4. PMID: 32871558, PMCID: PMC9730290, DOI: 10.6004/jnccn.2020.7610.Peer-Reviewed Original ResearchErythrocyte-stimulating agentsHematopoietic growth factorsGrowth factorSARS-CoV-2 infectionPandemic SARS-CoV-2 infectionGranulocyte colony-stimulating factorColony-stimulating factorTreatment of cancerThrombopoietin mimeticsHigh riskSuch growth factorsStimulating agentsPatientsCancerCOVID-19 eraCOVID-19 pandemicInfectionHigh-risk environmentsNeutropeniaThrombocytopeniaMorbidityChemotherapyFactorsAnemiaGroupNCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 12-22. PMID: 31910384, DOI: 10.6004/jnccn.2020.0002.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiosimilar PharmaceuticalsChemotherapy-Induced Febrile NeutropeniaDrug ApprovalDrug CostsEducation, Medical, ContinuingHematopoietic Cell Growth FactorsHumansMedical OncologyNeoplasmsOncologistsOrganizations, NonprofitPractice Guidelines as TopicRisk FactorsUnited StatesUnited States Food and Drug AdministrationConceptsFebrile neutropeniaNCCN guidelinesHematopoietic growth factorsGrowth factorManagement of FNTreatment of FNSelect patientsSupportive careNonmyeloid malignanciesCancer treatmentAppropriate evaluationAppropriate usePatientsRisk determinationTreatmentImportant updatesGuidelinesNeutropeniaProphylaxisMalignancyCliniciansFactorsCarePrevention
2018
Standardizing goals of care (GoC) documentation for new patients with metastatic disease.
Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.Peer-Reviewed Original ResearchGOC discussionsGOC documentationPatient-centered cancer carePalliative care teamEligible patientsSmart phrasesMetastatic diseaseNursing assessmentPatient assessmentCancer careQuality improvement toolsCare teamMetastatic cancerThird visitNew patientsProvider timeCare documentationPatientsBusy practiceProvider capacityBaseline dataElectronic documentationProvidersImprovement toolsFacilitative strategiesMeasuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.
Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. JCO Oncology Practice 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/jop.18.00419.Peer-Reviewed Original ResearchConceptsQuality of carePatient satisfactionClinical trialsSmilow Cancer HospitalUS academic centersCommunity oncology practicesPress Ganey scoresCenter physiciansAntineoplastic treatmentCancer HospitalOffice visitsCancer practiceTumor stagingCare centerOncology practiceTumor boardClinical careAcademic centersCase presentationPractice sitesCareCore measuresTrialsCommunity practiceClinical integrationNCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTract
2017
Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.Peer-Reviewed Original ResearchConceptsAdjuvant therapy decisionsRecurrence scoreChemotherapy useRS testingMedical oncologistsHistorical controlsChemotherapy decisionsTherapy decisionsEligibility criteriaNational Comprehensive Cancer Network guidelinesProspective quality improvement projectEarly-stage breast cancerAdjuvant chemotherapy recommendationsTime of diagnosisTime of surgeryQuality improvement projectTesting groupChemotherapy initiationChemotherapy recommendationsMedian timeTrial enrollmentNetwork guidelinesSurgical oncologistsClinical trialsBreast cancer
2011
Diffuse large cell lymphoma presenting as a sacral mass and lupus anticoagulant.
Ediriwickrema LS, Zaheer W. Diffuse large cell lymphoma presenting as a sacral mass and lupus anticoagulant. The Yale Journal Of Biology And Medicine 2011, 84: 433-8. PMID: 22180680, PMCID: PMC3238310.Peer-Reviewed Original Research
1995
Cord compression by extramedullary hematopoiesis in polycythemia vera.
Kalina P, Zaheer W, Drehobl KE. Cord compression by extramedullary hematopoiesis in polycythemia vera. AJR. American Journal Of Roentgenology 1995, 164: 1027-8. PMID: 7726026, DOI: 10.2214/ajr.164.4.7726026.Peer-Reviewed Original ResearchEndometrial adenocardinoma metastatic to bone diagnosed by fine needle aspiration biopsy
Ali SZ, Smilari AT, Zaheer W, Brones K. Endometrial adenocardinoma metastatic to bone diagnosed by fine needle aspiration biopsy. Journal of Surgical Pathology 1995, 1:137-141Peer-Reviewed Original ResearchCervical cancer screening in the elderly
Lichtman S, Zaheer W. Cervical cancer screening in the elderly. Primary Care and Cancer 1995, 15:21-22Peer-Reviewed Original Research
1994
HIV associated malignancy other than Hodgkin's lymphoma
Lichtman SM, Kaplan M, Zaheer W. HIV associated malignancy other than Hodgkin's lymphoma. Review Cancer (Madrid) 1994, 7(5):141-147Peer-Reviewed Original ResearchMesenchymoma of liver: care report and review of literature
Zaheer W, Allen SL, Ali SZ. Mesenchymoma of liver: care report and review of literature. Annals of Clinical and Laboratory Science 1994, 24(96):495-500Peer-Reviewed Case Reports and Technical Notes
1993
Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy.
Zaheer W, Friedland ML, Cooper EB, DoRosario A, Burd RM, Gagliardi J, Torstenson G. Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy. Cancer Investigation 1993, 11: 306-9. PMID: 8387390, DOI: 10.3109/07357909309024856.Peer-Reviewed Original Research